According to Theravance Biopharma 's latest financial reports the company's current revenue (TTM) is $61.51 M. In 2022 the company made a revenue of $51.34 M a decrease over the years 2021 revenue that were of $55.31 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $57.42 M | 11.84% |
2022 | $51.34 M | -7.17% |
2021 | $55.31 M | -23.03% |
2020 | $71.85 M | -2.12% |
2019 | $73.41 M | 21.61% |
2018 | $60.37 M | 292.37% |
2017 | $15.38 M | -68.37% |
2016 | $48.64 M | 15.48% |
2015 | $42.12 M | 260.42% |
2014 | $11.68 M | 5071.68% |
2013 | $0.22 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Corcept Therapeutics
CORT | $0.52 B | 751.13% | ๐บ๐ธ USA |
Collegium Pharmaceutical
COLL | $0.56 B | 821.68% | ๐บ๐ธ USA |
Catalyst Pharmaceuticals CPRX | $0.41 B | 568.75% | ๐บ๐ธ USA |
Catalent CTLT | $4.13 B | 6,622.48% | ๐บ๐ธ USA |